 |
市場調查報告書
商品編碼
1684654
環孢菌素市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測Cyclosporine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球環孢菌素市場價值為 33 億美元，預計 2025 年至 2034 年期間將以 14.5% 的複合年成長率強勁成長。隨著越來越多的人接受挽救生命的移植手術，對環孢菌素控制免疫反應的需求正在迅速增加。
除了器官移植之外，類風濕性關節炎、牛皮癬和自體免疫性重症肌無力等自體免疫疾病的日益普及也對市場產生了很大影響。環孢菌素已被證明是治療這些疾病的有效選擇，從而推動了其在製藥業的需求。隨著發展中地區醫療保健服務的不斷改善，越來越多的患者接受環孢素治療，進一步加速了其市場的成長。全球對器官捐贈認知的提高和移植技術的不斷進步也促進了環孢菌素的使用量的增加。
| 市場範圍 | |
|---|---|
| 起始年份 | 2024 |
| 預測年份 | 2025-2034 |
| 起始值 | 33億美元 |
| 預測值 | 127億美元 |
| 複合年成長率 | 14.5％ |
隨著先進免疫抑制療法研發投資的預計激增，預計未來幾年市場將迅速擴張。市場依適應症細分，包括移植排斥預防、自體免疫性重症肌無力、類風濕性關節炎、牛皮癬、乾眼症等。 2024 年，移植排斥預防佔最大的市場佔有率，價值 12 億美元。這種優勢是由於環孢菌素在預防器官排斥方面發揮的關鍵作用，特別是對於腎臟、肝臟和心臟移植患者。隨著移植技術的進步和術後護理的發展，對有效預防性治療的需求持續上升。
就劑型而言，環孢菌素有眼藥水、溶液、乳膏、軟膏和膠囊等形式。膠囊在 2024 年佔據最大的市場佔有率，佔整個市場的 31.8%。由於其易於使用且在長期治療中有效，特別是對於自體免疫疾病和器官移植，因此成為首選形式。封裝技術的進步提高了環孢菌素的生物利用度和穩定性，推動了該領域的進一步成長。
美國環孢菌素市場價值在 2024 年達到 11 億美元，由於其先進的醫療保健系統、免疫抑制治療的高採用率以及自體免疫疾病等慢性病和器官移植需求的廣泛流行，該市場處於領先地位。知名產業參與者的存在，加上持續的創新和有利的報銷政策，為環孢素市場的持續成長創造了肥沃的環境。
目錄
第 1 章：方法論與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業衝擊力
- 成長動力
- 自體免疫疾病盛行率不斷上升
- 器官移植程序的成長
- 增加潛在臨床候選藥物
- 產業陷阱與挑戰
- 不良副作用
- 成長動力
- 成長潛力分析
- 監管格局
- 管道分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 策略儀表板
第 5 章：市場估計與預測：按適應症，2021 年至 2034 年
- 主要趨勢
- 移植排除預防
- 類風濕關節炎
- 牛皮癬
- 自體免疫性重症肌無力
- 乾眼症
- 其他適應症
第 6 章：市場估計與預測：按劑型，2021 – 2034 年
- 主要趨勢
- 膠囊
- 眼藥水
- 解決方案
- 乳霜和軟膏
第 7 章：市場估計與預測：按管理路線，2021 年至 2034 年
- 主要趨勢
- 口服
- 主題
- 腸外
第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區，2021 年至 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第10章：公司簡介
- Avet Pharmaceuticals
- AdvaCare Pharm
- AbbVie
- Apotex
- Cipla
- Dr. Reddy's Laboratories
- Novartis
- Santen Pharmaceutical
- Sun Pharmaceutical Industries
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries
- Viatris
The Global Cyclosporine Market, valued at USD 3.3 billion in 2024, is expected to experience robust growth at a CAGR of 14.5% from 2025 to 2034. This impressive expansion is mainly driven by the rising demand for organ transplantation procedures, which depend on immunosuppressive therapies to prevent organ rejection. As more people undergo life-saving transplants, the need for cyclosporine to manage immune responses is increasing rapidly.
In addition to organ transplants, the market is being significantly influenced by the growing prevalence of autoimmune disorders such as rheumatoid arthritis, psoriasis, and autoimmune myasthenia gravis. Cyclosporine has proven to be an effective treatment option for managing these conditions, boosting its demand in the pharmaceutical industry. As healthcare access continues to improve in developing regions, more patients are being treated with cyclosporine, further accelerating its market growth. The global push toward increasing awareness of organ donation and the continuous advancements in transplant technologies are also contributing to the increasing usage of cyclosporine.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $3.3 Billion |
| Forecast Value | $12.7 Billion |
| CAGR | 14.5% |
With a projected surge in R&D investments for advanced immunosuppressive therapies, the market is expected to expand rapidly in the coming years. The market is segmented by indication, including transplant rejection prophylaxis, autoimmune myasthenia gravis, rheumatoid arthritis, psoriasis, dry eye, and others. In 2024, transplant rejection prophylaxis held the largest share of the market, valued at USD 1.2 billion. This dominance is due to the critical role cyclosporine plays in preventing organ rejection, particularly in kidney, liver, and heart transplant patients. As transplant techniques improve and post-surgical care evolves, the demand for effective prophylactic treatments continues to rise.
When it comes to dosage forms, cyclosporine is available in eye drops, solutions, creams and ointments, and capsules. Capsules accounted for the largest market share in 2024, making up 31.8% of the total market. Their ease of use and effectiveness in long-term treatments, particularly for autoimmune diseases and organ transplants, make them the preferred form. Advances in encapsulation technologies have enhanced cyclosporine's bioavailability and stability, driving further growth in this segment.
The U.S. cyclosporine market, valued at USD 1.1 billion in 2024, stands as a leader due to its advanced healthcare system, high adoption rates of immunosuppressive treatments, and the widespread prevalence of chronic conditions like autoimmune disorders and the need for organ transplants. The presence of prominent industry players, coupled with continuous innovation and favorable reimbursement policies, creates a fertile environment for the sustained growth of the cyclosporine market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing prevalence of autoimmune diseases
- 3.2.1.2 Growing organ transplantation procedures
- 3.2.1.3 Increase in potential clinical pipeline candidates
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Adverse side effects
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Transplant rejection prophylaxis
- 5.3 Rheumatoid arthritis
- 5.4 Psoriasis
- 5.5 Autoimmune myasthenia gravis
- 5.6 Dry eye
- 5.7 Other indications
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Capsule
- 6.3 Eye drops
- 6.4 Solutions
- 6.5 Creams and ointments
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Topical
- 7.4 Parenteral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 Avet Pharmaceuticals
- 10.2 AdvaCare Pharm
- 10.3 AbbVie
- 10.4 Apotex
- 10.5 Cipla
- 10.6 Dr. Reddy's Laboratories
- 10.7 Novartis
- 10.8 Santen Pharmaceutical
- 10.9 Sun Pharmaceutical Industries
- 10.10 Strides Pharma Science Limited
- 10.11 Teva Pharmaceutical Industries
- 10.12 Viatris
